Business Context and Reporting Period
Company: Abbott Laboratories (ABT)
Filing Type: Form 8-K (Current Report)
Date of Report: April 10, 2026
Event: Preliminary court approval of a proposed settlement regarding pending shareholder derivative litigation.
Financial Metrics
This filing does not contain financial performance data. No revenue, profit, cash flow, margin, debt, or liquidity metrics are reported in this document.
Material Changes
The filing reports a procedural development in the consolidated shareholder derivative lawsuit titled In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation. On April 10, 2026, the United States District Court for the Northern District of Illinois signed an order preliminarily approving the proposed settlement, directing the issuance of notice to shareholders, and setting a date for a final settlement hearing.
Guidance, Outlook, and Risks
- Legal Contingency: The litigation involves claims against certain current and former directors and officers. The preliminary approval indicates the court has not yet finalized the settlement, pending a final hearing.
- Management Commentary: The filing references prior disclosures in the 2024 and 2025 Form 10-K filings regarding the existence of these six consolidated lawsuits.
- Outlook: No financial guidance or operational outlook is provided in this report.
Key Facts for Investor Verification
- Verify the specific terms and financial value of the proposed settlement in the attached Exhibit 99.1 (Notice of Proposed Settlement).
- Confirm the date and outcome of the final settlement hearing scheduled by the court.
- Review the 2024 and 2025 Form 10-K filings for historical context on the infant formula derivative litigation.
- Monitor for any future 8-K filings regarding the final court approval or rejection of the settlement.